(4-cyclohexyl-butyl)-methyl-amine | 149080-32-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (4-cyclohexyl-butyl)-methyl-amine
• 英文别名: (4-Cyclohexyl-butyl)-methyl-amin；4-Methylamino-1-cyclohexyl-butan；4-cyclohexyl-N-methylbutan-1-amine
• CAS: 149080-32-0
• 化学式: C₁₁H₂₃N
• 分子量: 169.31
• InChiKey: QMEGENDOPKVWTA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-环己基溴乙烷 、 (4-cyclohexyl-butyl)-methyl-amine 生成 (2-cyclohexyl-ethyl)-(4-cyclohexyl-butyl)-methyl-amine
  参考文献：
  名称：

  Antispasmodics. III

  摘要：

  DOI：

  10.1021/ja01873a004
• 作为产物：
  描述：

  (4-溴丁基)-环己烷 、 甲胺 在 乙醇 作用下， 生成 (4-cyclohexyl-butyl)-methyl-amine
  参考文献：
  名称：

  Antispasmodics. I

  摘要：

  DOI：

  10.1021/ja01870a029

文献信息

• 7-Oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
  申请人：E.R. SQUIBB & SONS, INC.

  公开号：EP0374952A2

  公开（公告）日：1990-06-27

  7-Oxabicycloheptane substituted prostaglandin analogs which are thromboxane A2 (TxA2) receptor antagonists or combined thromboxane A2 receptor antagonists/thromboxane synthase inhibitors useful, for example, in treating thrombotic and vasospastic disease have the structural formula wherein m is 1, 2 or 3; n is 0, 1, 2, 3 or 4; Z is -(CH2)2- or -CH=CH-, with the proviso when Z is -CH = CH-, n is 1, 2, 3 or 4; R is C02H, CO2lower alkyl, CH2OH, CO2alkali metal, CONHSOR3, CONHR3a or -CH2-5-tetrazolyl, X is 0, S or NH; and where R1, R2, R3 and R3a are as defined herein.

  7-氧杂双环庚烷取代的前列腺素类似物是血栓素 A2（TxA2）受体拮抗剂或血栓素 A2 受体拮抗剂/血栓素合成酶联合抑制剂，可用于治疗血栓性疾病和血管痉挛性疾病等，其结构式为 其中 m 是 1、2 或 3；n 是 0、1、2、3 或 4；Z 是-(CH2)2- 或-CH=CH-，但当 Z 是-CH=CH-时，n 是 1、2、3 或 4；R 是 C02H、CO2lower 烷基、CH2OH、CO2 碱金属、CONHSOR3、CONHR3a 或-CH2-5-四唑基，X 是 0、S 或 NH；其中 R1、R2、R3 和 R3a 如本文所定义。
• AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS
  申请人：ZERIA PHARMACEUTICAL CO., LTD.

  公开号：EP0870765A1

  公开（公告）日：1998-10-14

  The present invention relates to an aminothiazole derivative represented by the following formula (I): wherein R1, R2 and R3 each independently represents a hydrogen atom, a hydroxy group, a lower alkyl group, a lower alkoxy group or the like; R4 represents a hydrogen atom or a lower alkyl group; R5 represents a hydrogen atom, a halogen atom or a lower alkyl group; m stands for an integer of 0 to 4, A represents a substituted amino group, a substituted imino group, a heterocyclic group or the like; and B stands for an imino group or an oxygen atom, a medicament containing it and an intermediate for the preparation of said compound. The compound has strong restoration effects on dysmotility in the gastrointestinal tract and at the same time has high safety so that it is useful as an excellent gastroprokinetic.

  本发明涉及下式（I）所代表的氨基噻唑衍生物： 其中 R1、R2 和 R3 各自独立地代表氢原子、羟基、低级烷基、低级烷氧基或类似基团；R4 代表氢原子或低级烷基；R5 代表氢原子、卤素原子或低级烷基；m 代表 0 至 4 的整数；A 代表取代的氨基、取代的亚氨基、杂环基团或类似基团；B 代表亚氨基或氧原子。该化合物对胃肠道运动障碍有很强的修复作用，同时具有很高的安全性，因此可作为一种很好的胃动力药。
• Interphenylene 7-oxabicyclo[2.2.1]heptane oxazoles. Highly potent, selective, and long-acting thromboxane A2 receptor antagonists
  作者：Raj N. Misra、Baerbel R. Brown、Philip M. Sher、Manorama M. Patel、Steven E. Hall、Wen Ching Han、Joel C. Barrish、Octavian Kocy、Don N. Harris

  DOI：10.1021/jm00062a013

  日期：1993.5

  A series of interphenylene 7-oxabicyclo[2.2.1]heptane oxazoles (2) were prepared and evaluated for their thromboxane (TxA2) antagonistic activity in vitro and duration of action in vivo. Examination of the carboxyl side chain indicated that the interphenylene ring substitution pattern and, to a lesser extent, chain length were important factors in determining TxA2 antagonistic potency. For the carboxyl side chain, ortho substitution, a single methylene spacer between the interphenylene and oxabicycloheptane rings, and a propionic acid side-chain length were determined to be optimal. With respect to the oxazole side chain a wide range of amide substituents with diverse structures and lipophilicities were compatible with potent antagonistic activity. Finally. an acidic functional group on the alpha-chain and a hydrogen bond acceptor on the 4-position of the oxazole ring were critical for potent activity. From the analogs prepared 42 BMS-180,291: [(+)-1S-(1alpha,2alpha,3alpha,4alpha)]-2-[[3-[4-[(n-pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid} was found to be a potent, selective, and orally-active TxA2 antagonist with a long duration of action and has been selected as a candidate for clinical development. In human platelet-rich plasma, 42 inhibited arachidonic acid (800 muM) and U-46,619 (10 muM) induced aggregation with I50 values of 7 and 21 nM, respectively. Radioligand binding studies of 42 with [H-3]-SQ 29,548 showed a K(d) value of 4.0 +/- 1.0 nM in human platelet membranes. Both in vitro and in vivo studies indicated 42 was devoid of direct agonistic activity. In vivo 42 (0.2 mg/kg, po) showed extended protection (T50 = 14.4 h) from U-46,619 (2 mg/kg, iv) induced death in mice, and a single oral dose of 42 (3 mg/kg) abolished U46,619-induced platelet aggregation ex vivo in African green monkeys for >24 h.
• Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use
  申请人：Min Jaeki

  公开号：US20120022070A1

  公开（公告）日：2012-01-26

  Novel classes of molecular chaperone Heat shock protein 90 (Hsp90) inhibitors are disclosed. These compounds are useful in treating and preventing cancer and other Hsp90-related diseases and conditions, such as inflammation and neurodegenerative disorders. Methods of treating and preventing cancer and other Hsp90 related diseases and conditions are disclosed that include administering to the subject a therapeutically effective amount of an Hsp90 inhibitor. Methods of preparing the novel Hsp90 inhibitors are also provided.
• US5100889A
  申请人：——

  公开号：US5100889A

  公开（公告）日：1992-03-31